↓ Calculate your dosage
"Doctor Explains The Truth About MOTS-c & If It's Safe (nobody is saying this)" — Dr. Jones, DC, uploaded 2026-06-18, 14:52, ~58,800 views as of 2026-07-31. Metadata pulled live via yt-dlp --skip-download --print this session — not from memory. Dr. Jones is a chiropractor (DC), not a physician — credential labeled honestly here and everywhere on this page; his content is shown as one voice in the "PubMed vs. the Doctors" section below, set against the controlled literature.
0
Completed Human Drug Trials
Every published human MOTS-c study is observational, genetic, or exercise-biomarker research. Nobody has published results from a completed trial that actually injected native MOTS-c into people.
Feb 2026
The First One Just Started
Hudson Biotech's Phase 2a placebo-controlled trial (NCT07505745) began enrolling adults with prediabetes/obesity in February 2026 — still recruiting as of July 2026, no results yet.
27,527
People in the Largest Genetic Study
A 2021 meta-analysis across three Japanese cohorts found the mtDNA variant behind MOTS-c is linked to higher type 2 diabetes risk in men — the opposite direction from the "longevity gene" framing you'll see marketed.
$40–95
Monthly Cost, Gray Market
"Research use only" MOTS-c vials, no prescription, no FDA purity oversight, at commonly reported community dosing.
MOTS-c is a 16-amino-acid peptide encoded inside a short reading frame that overlaps the mitochondrial 12S rRNA gene — hence the name, Mitochondrial Open Reading frame of the 12S rRNA Type-c. Unlike BPC-157 or TB-500, which are lab-synthesized sequences derived from other proteins, MOTS-c is literally made by your own mitochondrial DNA and already circulates in your blood; injected "MOTS-c" products are a synthetic copy of a peptide your cells already produce. It was discovered and characterized in 2015 by Changhan Lee, Pinchas Cohen, and colleagues at USC's Leonard Davis School of Gerontology. Under metabolic stress, MOTS-c translocates from the mitochondria to the nucleus and activates AMPK — the same master energy-sensing pathway targeted by exercise and by the generic diabetes drug metformin — which is the basis for the "exercise mimetic" and "exercise in a vial" marketing language you'll see on peptide-clinic sites. A 2023 review of the therapeutic literature (PMID 36761202, Zheng et al., Front Endocrinol) found the mechanistic case consistent across aging, cardiovascular, insulin-resistance, and inflammation models — while noting plainly that "MOTS-c has been used less frequently in disease treatment, and no effective method of applying MOTS-c in the clinic has been developed."
Mechanism 1 — Discovery & AMPK Activation (Mouse)
16 Amino Acids, One Gene
In the original 2015 paper, daily MOTS-c injections in high-fat-diet mice prevented and partially reversed diet-induced obesity and insulin resistance, acting through the folate-AICAR-AMPK pathway in skeletal muscle. This is the foundational finding the entire "exercise mimetic" story rests on — and it is a mouse study, not a human one.
Mechanism 2 — Exercise Raises It (Human, Observational)
Rises With Exertion
A real human finding: a single bout of acute endurance exercise measurably raised circulating MOTS-c levels in study participants. This is genuine human data — but it shows the body releases more of its own MOTS-c when you exercise, which is a different claim from "injecting extra MOTS-c gives you the benefits of exercise."
Mechanism 3 — Diabetic Heart Mitochondria (Rat)
15 mg/kg, 3 Weeks
In rats with diet/streptozotocin-induced type 2 diabetes, three weeks of daily MOTS-c injections (15 mg/kg) partially restored cardiac mitochondrial oxygen flux and reduced excess reactive-oxygen production compared with untreated diabetic rats — a real preclinical signal in a disease-relevant tissue, not yet tested in a human heart. A separate 2022 mouse study found daily MOTS-c during pregnancy alleviated hyperglycemia and improved glucose tolerance in a gestational-diabetes model (
PMID 34798268, Yin/Pan et al.,
Pharmacol Res) — both animal studies, neither yet tested in pregnant humans.
Mechanism 4 — Same Pathway as Metformin, Unconfirmed Interaction
Overlap ≠ Proven Link
MOTS-c's proposed mechanism substantially overlaps metformin's (folate-AICAR-AMPK). When researchers actually measured it, 24 weeks of metformin in breast cancer patients did not produce a statistically significant change in circulating MOTS-c — the hoped-for interaction didn't show up when tested directly. Reported honestly here rather than assumed.
This is the single most important honest picture on this page: real human research exists — genetic studies, exercise-biomarker studies, disease-correlation studies — but none of it involved giving anyone the peptide as a treatment and measuring what happened. A 2024 systematic review and meta-analysis pooling 602 participants across 6 case-control studies confirmed the same pattern: consistent correlations between circulating MOTS-c and metabolic markers, with no interventional data included because none exists (PMID 39160573, Zhou et al., Diabetol Metab Syndr 2024). That trial only began enrolling six months ago.
Animal / Cell / Mechanistic
Mouse, rat, and cell-culture work. Consistent AMPK-activation and metabolic signal across independent labs since 2015.
Human Studies (Non-Interventional)
Genetic/polymorphism association studies, circulating-level correlation studies, exercise-biomarker studies. Real human data — none of it a drug trial.
Completed Placebo-Controlled Drug Trials
Zero, for native-sequence MOTS-c. The first one (Hudson Biotech, Phase 2a) began enrolling February 2026 and has not reported results as of this writing.
Every row below is real, published human research. None of them gave a person MOTS-c and measured a clinical outcome — they measured the MOTS-c your body already makes, or the gene that encodes it. The last row is the one study that will finally test the drug directly, still in progress.
| # |
Study / PMID |
Type |
n |
What It Actually Found |
Outcome |
| 1 |
Zempo et al. · PMID 33468709 — 3-cohort meta-analysis (J-MICC, MEC, TMM) |
Genetic / Polymorphism |
27,527 |
The East-Asian-specific m.1382A>C (K14Q) variant is associated with higher type 2 diabetes prevalence in men, especially sedentary men — a "pro-diabetogenic" reading of the same gene variant other researchers have linked to longevity (see row 2). |
Real, but cuts against the "longevity gene" story |
| 2 |
Fuku et al. · PMID 26289118 — hypothesis commentary |
Genetic / Hypothesis |
n/a (commentary) |
Proposes the same m.1382A>C variant "may be among the putative biological mechanisms" behind exceptional longevity in Japanese centenarians. This is an editorial-style hypothesis piece, not a tested causal claim — and it sits in direct tension with row 1's larger, later functional study. |
Hypothesis, not proof |
| 3 |
Kim · PMID 39457696 — cross-sectional |
Genetic / Polymorphism |
683 |
Older Korean men carrying the C-allele had significantly higher muscle mass and grip strength than A-allele carriers (no difference in women) — the opposite direction you'd expect if the C-allele purely "weakens" MOTS-c function. |
Complicates the risk-allele story |
| 4 |
Kumagai et al. · PMID 34728329 |
Genetic / Polymorphism |
Not reported in abstract |
The K14Q polymorphism is associated with differences in skeletal-muscle fiber-type composition and muscular performance — further evidence the variant has a real functional effect, independent of whether that effect is "good" or "bad." |
Functional, direction-neutral |
| 5 |
von Walden et al. · PMID 34351816 |
Exercise / Biomarker |
Not reported in abstract |
Acute endurance exercise measurably raised circulating MOTS-c in humans — real evidence the peptide is part of the body's own exercise-response system, not evidence that injecting it replicates exercise. |
Real signal, biomarker only |
| 6 |
Dieli-Conwright et al. · PMID 34413391 — RCT sub-analysis |
Exercise / Biomarker |
Breast cancer survivors, secondary analysis |
A 16-week aerobic + resistance exercise program changed MOTS-c levels in Hispanic and Non-Hispanic White breast cancer survivors — MOTS-c was the measured outcome of an exercise trial, not the treatment being tested. |
Biomarker of a real exercise RCT |
| 7 |
Filibeli et al. · PMID 41945630 |
Genetic / Case-control |
246 (121 PCOS, 125 control) |
No significant difference in MOTS-c levels between adolescents with PCOS and controls (p=0.059); every participant carried the wild-type A/A genotype — the variant is essentially absent outside East Asian populations, confirming its population-specific framing. |
Null result |
| 8 |
Ikonomidis et al. · PMID 32052315 |
Disease Correlation |
Type 2 diabetics with CAD |
Lower MOTS-c (paired with higher β-amyloid) predicted worse outcomes in diabetics with revascularized coronary artery disease and high platelet reactivity — an association, not a treatment result. |
Prognostic biomarker |
| 9 |
Hudson Biotech Phase 2a · NCT07505745 |
Placebo-Controlled RCT |
120 (target) |
The actual drug trial. Adults with prediabetes/overweight-obesity, randomized 1:1 to subcutaneous MOTS-c or placebo, once daily for 12 weeks, primary endpoint OGTT insulin sensitivity (Matsuda Index) plus safety through week 16. Enrollment began February 2026. No results published yet. |
In progress — the one to watch |
Reality check (honest reading): Everything above rows 1–8 is real, peer-reviewed, and worth taking seriously — but it is genetic association data, exercise-biomarker data, and disease-correlation data, not evidence that giving someone MOTS-c produces a clinical benefit. The genetic story itself is genuinely contested: the same mtDNA variant has been proposed as a longevity marker (row 2, a hypothesis piece) and shown, in a far larger functional study, to raise diabetes risk in men (row 1) and raise muscle mass in older men (row 3) — three different papers pointing in three different directions from the same single-letter DNA change. That is not a page failing to make up its mind; that is what the actual literature shows, and a reader deserves to see the contradiction rather than a tidied-up story. The one study that will actually test the drug in people — row 9 — started six months ago and won't have an answer for a while yet.
MOTS-c sits in an unusual spot: it's cheap on the gray market like most peptides on this site, but — unlike BPC-157 — it is a genuine target of patent-driven biotech investment. One of the two companies in this story has already gone out of business.
Unregulated / T5
Gray-Market MOTS-c Vials
$40–110
per 10 mg vial ($3–13/mg) · no Rx, no FDA purity oversight
Standard community protocols (5–15 mg/week) run roughly $40–95/month depending on vendor and dose tier chosen (see calculator below)
Same Pathway, Decades of Data
Metformin (Generic)
$4–10
per month · oral, FDA-approved, first-line T2D drug since the 1990s
Activates the same AMPK pathway MOTS-c is proposed to work through — decades of real-world human safety and efficacy data that MOTS-c does not yet have
Discontinued
CB4211 (Patented MOTS-c Analog)
$0
not available at any price — developer dissolved
The one company with both a patent and a completed human trial of a MOTS-c-class molecule (CohBar Inc.) went through a failed 2023 merger, Nasdaq delisting, and planned liquidation before advancing past Phase 1 — see Follow the Money below
Exercise (vigorous, 75–149 min/wk)
$0
zero direct cost
Hazard ratio 0.81 for all-cause mortality vs. no vigorous activity — about 19% lower. 116,221 US adults, 30 years follow-up. This is also the one intervention proven to raise your body's own circulating MOTS-c (see Mechanism 2 above) — an observational cohort, so association not a randomized effect.
SS-31 / NAD+ (This Site's Other Mitochondrial Pages)
See pages
different mechanisms, different evidence bases
Often stacked together for a combined "mitochondrial protocol." This page covers MOTS-c alone — for the combined stack, dosing sequence, and interaction questions, see this site's
Mitochondrial Triple Stack page.
→ Cross-reference, this site
💰 Follow the Money — Precisely Stated
MOTS-c's discoverer has a direct, disclosed financial stake in its commercial development — and the company he co-founded to develop it has since dissolved. Pinchas Cohen, the USC gerontologist whose lab identified MOTS-c in 2015, co-founded CohBar Inc. and holds patent protection (US 11,111,271) on MOTS-c-derived analogs. His own 2021 paper on the diabetes-risk polymorphism discloses it directly: "Pinchas Cohen is a consultant and stockholder of CohBar Inc." That is a real, disclosed conflict — precisely stated, it means the person best positioned to shape how MOTS-c's biology gets framed also stood to profit from a positive read of it, which is exactly why this page cites the Zempo 2021 paper's less flattering finding (pro-diabetogenic in men) at equal weight to the more flattering 2015 longevity hypothesis.
CohBar's own patented analog, CB4211, is the closest thing to a completed human MOTS-c drug trial that exists — a Phase 1a/1b RCT in NAFLD/obesity (n=20: 11 treated at 25 mg SC daily for 28 days vs. 9 placebo) reported "positive topline" results (reduced ALT, AST, and glucose vs. placebo, no serious adverse events) via company press release and a 2021 late-breaker presentation at The Liver Meeting. We could not locate a peer-reviewed publication of these results in PubMed — this is company-reported data on a small, short trial of an analog molecule, not the native peptide, and it has never passed peer review as far as we can determine.
The company then ran out of runway, unrelated to any negative trial result. CohBar entered a 2023 merger agreement with Morphogenesis Inc. to pivot into oncology; the merger collapsed, Nasdaq delisted CohBar in November 2023 as a "public shell," and the company announced plans to liquidate and dissolve. Its own web domain no longer resolves as of this session. Nobody is currently funding further development of CB4211.
The precise claim: this is different from most of this site's peptide-funding stories, where the problem is a cheap, unpatentable compound nobody profits enough from to fund a real trial. MOTS-c is the opposite case — it is patentable, a company did patent an analog and run a small positive-signal human trial, and the barrier to a bigger trial turned out to be corporate survival, not a lack of commercial incentive. Meanwhile, a separate, newer company (Hudson Biotech) is now running the first trial of the native peptide itself. Neither fact tells you whether MOTS-c works — they tell you why, six years after discovery, we still don't have a real answer.
There is no FDA-approved dose and — unlike SS-31 or tirzepatide on this site — no published trial dose either, because the first human trial hasn't reported results. Every number below is a community or telehealth-clinic protocol, not a clinical recommendation. The calculator underneath does the reconstitution math for whichever one you're looking at.
Lower / Starter
2.5 mg, 3x/week SC
About 7.5 mg/week. The commonly reported low-end starting point, used to check tolerance before increasing.
Clinic / Telehealth Standard
5 mg, 2–3x/week SC
About 10–15 mg/week. The dose most often cited across telehealth peptide-clinic protocols, typically physician-supervised but not FDA-recognized for any indication.
CLINICAL PRACTICE
Upper / Extended Cycle
10 mg, 2x/week SC
About 20 mg/week — the upper end of reported community use. Some protocols instead run "4 injections over 20 days, then months off" rather than continuous dosing. This is the least-evidenced end of an already uncontrolled range.
What's Actually Missing
No Trial Dose
The Hudson Biotech Phase 2a trial (the first real human dose-finding data) has not published its actual dose or results. Every tier above is extrapolated from mouse dosing and community reporting, not from a human study of the real drug.
MOTS-c just went through the exact same FDA advisory process as BPC-157, TB-500, and Epithalon on this site — including its own FDA staff recommending against it, and a committee vote overruling that recommendation.
FDA — April 15, 2026
Removed From Category 2 "Significant Safety Risk" List
The FDA removed MOTS-c, alongside 11 other peptides (including BPC-157, TB-500, KPV, and Epitalon), from Category 2 of its 503A bulk drug substances list following withdrawal of the original nominations. This removes an explicit "significant safety risk" designation — it does
not constitute approval or clear MOTS-c for legal compounding.
→ Orrick legal analysis of the FDA announcement
FDA — July 23, 2026, PCAC Briefing (Primary Document)
FDA Staff: "NOT Be Included"
The FDA's own Points to Consider document for the Pharmacy Compounding Advisory Committee states, verbatim:
"FDA is proposing that MOTS-c (free base) NOT be included on the 503A Bulks List" and
"FDA is proposing that MOTS-c acetate NOT be included on the 503A Bulks List." Career FDA scientists concluded the safety and effectiveness evidence was insufficient — the same conclusion they reached for BPC-157, TB-500, and KPV, presented the same day.
→ FDA PCAC Briefing Document, July 23–24, 2026 (primary document, page 7)
PCAC Committee Vote — July 23, 2026
Overruled Staff, 7–5, Two Abstentions
The advisory committee voted to recommend including MOTS-c on the 503A compounding list anyway — the same overrule pattern seen with BPC-157, KPV, and TB-500 at the same meeting. This is advisory only; it does not bind the FDA, which had not issued a final decision as of this writing.
→ FDA PCAC meeting page (primary) ·
→ Peptide Dossier vote-tally summary
WADA / USADA
Prohibited At All Times (S4.4.1)
Unlike SS-31 on this site, MOTS-c's sport status is unambiguous: USADA states MOTS-c
"is prohibited at all times under Section 4.4 Metabolic Modulators, 4.4.1. Activators of the AMP-activated protein kinase (AMPK)" on the WADA Prohibited List. No Therapeutic Use Exemption is available, since MOTS-c has no approved medical use.
→ USADA — "What is the MOTS-c peptide?"
Two equal pillars — the controlled/observational research above, set against the credentialed voices actually discussing MOTS-c publicly. This is a genuinely new compound in clinical use, and that shows in who's willing to talk about it.
📚 What the Literature Shows
The mouse/cell mechanistic story is real and replicated: MOTS-c activates AMPK, reduces diet-induced obesity, and improves insulin sensitivity in high-fat-diet mice, with a consistent signal across independent labs since 2015.
Every published human study is observational or genetic. Circulating MOTS-c rises with exercise (real, human) — but that's a biomarker response, not proof injecting extra MOTS-c replicates exercise's benefits.
The genetic story genuinely contradicts itself across papers: one small hypothesis paper links the m.1382A>C variant to Japanese-centenarian longevity; a much larger functional meta-analysis (n=27,527) found the same variant raises diabetes risk in men; a third study found C-allele carriers have more muscle mass. This page reports the contradiction rather than resolving it for you.
The first placebo-controlled human drug trial (Hudson Biotech, Phase 2a) began enrolling in February 2026 and has not reported results — it is simply too early to know whether the mouse-model insulin-sensitivity story replicates in people.
🩺 What Practitioners Report
Dr. Jones, DC (chiropractor; joints/rehab lane, this site's banked expert roster) —
"Doctor Explains The Truth About MOTS-c & If It's Safe (nobody is saying this)" (2026-06-18, 14:52, ~58,800 views as of 2026-07-31). Frames MOTS-c's safety picture cautiously, emphasizing how little human trial data actually exists — broadly consistent with the evidence-stack finding above. Credential labeled honestly: chiropractor, not a physician.
Dr. Ahmet Ergin, MD, FACE — board-certified endocrinologist, Cleveland Clinic fellowship-trained, host of the SugarMD diabetes-education channel. Credential independently verified via his
LinkedIn profile and
practice site.
"The Peptide That Could Change Diabetes Forever: MOTS-c" (2026-06-17, 8:53, ~7,700 views as of 2026-07-31). A genuine Pass-3/8 find: an actual board-certified endocrinologist — the specialty most directly relevant to MOTS-c's proposed insulin-sensitizing mechanism — discussing it on record. No patient-outcome numbers or product sale detected in the video.
What we searched for and did not find: a licensed clinician publishing a case series or specific patient-outcome numbers for native MOTS-c (the Pass-3 standard this site applies to BPC-157 and SS-31). We found none — the compound is genuinely too new to clinical use for that track record to exist yet. Telehealth clinic marketing pages claim large patient volumes (one site claims a Miami clinic has treated "2,000+ patients") without naming a clinician or publishing differentiated outcomes; we could not independently verify that specific claim and are not printing it as fact.
Real-World Use
The people actually buying MOTS-c today are longevity biohackers and telehealth "metabolic optimization" patients — people who have plateaued on diet and exercise alone, or who are drawn to the "exercise mimetic" framing directly. Commonly reported anecdotal effects: subjective energy improvement, easier fat loss when combined with diet and training, and improved gym recovery. None of this is backed by a placebo-controlled human trial — the one trial that exists is still enrolling.
Removal asymmetry — Pass 8 note: Our yt-dlp search of "MOTS-c peptide doctor mitochondria" surfaced ten results, all currently live, spanning 2025–2026, from independent chiropractors, an endocrinologist, longevity-podcast hosts, and regenerative-medicine clinic channels. No evidence of a removal or demonetization campaign against MOTS-c content was found — bounded to this single search session, reported honestly rather than assumed.
Unlike SS-31 on this site, MOTS-c has no FDA label and no completed human trial to pull safety data from. What follows is what we actually know, stated plainly as either reassuring or genuinely unknown — never blurred into each other.
No Human Trial Safety Data (Native Peptide)
Genuine Unknown
Because no completed interventional trial of native MOTS-c exists, there is no FDA-tabulated adverse-event table, no documented drug-interaction study, and no established contraindication list for it. The one relevant human safety signal comes from CB4211, a different, patented analog molecule: a company-reported, unpublished Phase 1a/1b (n=20, 28 days) found it "well-tolerated" with no serious adverse events. That is thin, short-duration, unpublished evidence about a related-but-different molecule — not safety data for what's sold as MOTS-c today.
→ ClinicalTrials.gov NCT07505745 (in progress) · CohBar 2021 press release (unpublished, analog molecule)
It's Already In Your Blood
Endogenous Peptide
MOTS-c is not a foreign molecule — your own mitochondria already produce and release it, more so with exercise. That's genuinely reassuring context, but it does not answer the safety question for sustained injected doses well above normal circulating levels, which is genuinely unstudied territory in humans.
→ PMID 34351816 (von Walden et al., 2021)
One Encouraging Cancer Signal — Narrowly Stated
Ovarian Cancer, Cell/Mouse
A 2024 study found MOTS-c suppressed ovarian cancer cell proliferation and progression in cell and mouse models, via a specific ubiquitination mechanism. This is a reassuring direction — the opposite concern some other longevity peptides raise — but it's one tumor type, in preclinical models, and must not be generalized into "MOTS-c prevents cancer."
Sourcing / Purity Risk
HIGH (gray-market)
"Research use only" MOTS-c vials sold online carry no sterility testing requirement, no potency verification, and no cold-chain guarantee. Independent testing of research-peptide vendors generally has repeatedly found under- or mis-dosed product across this category — the same risk documented on this site's other peptide pages applies here.
→ vendor-testing pattern per market reporting, this site's standing methodology
⛔ What we genuinely don't know: There is no established dose-response safety curve, no drug-interaction data, and no population-level adverse-event record for native MOTS-c in humans at any dose. Anyone on diabetes medication (given the proposed AMPK/insulin-sensitizing overlap with metformin and GLP-1 drugs), anyone with active cancer under treatment, and anyone pregnant or breastfeeding should treat this as genuinely unstudied territory — an absence of documented harm is not the same thing as evidence of safety, and this page will not pretend otherwise.
✓ What's genuinely reassuring: No organ-toxicity signal, overdose case, or serious-adverse-event report was found anywhere in the mouse, rat, or limited human literature we reviewed — including at the relatively high 15 mg/kg rat dose. MOTS-c is endogenous, not a synthetic foreign sequence, and the one preclinical cancer signal found runs in the protective direction. The honest gap here is efficacy and dosing data, not a documented danger signal — but "we haven't found harm yet" in a body of research this small is a much weaker claim than the equivalent statement on SS-31, which has an actual FDA safety table behind it.
An honest read of MOTS-c in 2026
What it is: A 16-amino-acid peptide your own mitochondria already make, encoded in a gene overlapping the 12S rRNA region of your mitochondrial DNA. Discovered in 2015 at USC, it activates AMPK — the same pathway exercise and metformin engage — which is why it's marketed as an "exercise mimetic." The mouse data behind that story is real and consistently replicated.
Who's using it: Longevity biohackers and telehealth "metabolic optimization" patients buying research-chemical vials for $40–110 each, self-administering 5–20 mg/week with no established dose, no FDA oversight of purity, and no completed human trial telling them what to expect.
What the law says: The FDA removed MOTS-c from its "significant safety risk" Category 2 list in April 2026, but its own staff then formally recommended against adding it to the legal compounding list in July 2026 — an advisory committee overruled that recommendation 7–5, non-bindingly. It's explicitly banned in Olympic and professional sport under WADA's AMPK-activator category, with zero ambiguity and no exemption available.
What the research shows: A genuinely strong, consistent mouse and cell mechanistic story. Real human data that is entirely genetic, observational, and biomarker-based — and that data actually contradicts itself: the same gene variant has been floated as a longevity marker and shown, in a much bigger study, to raise diabetes risk in men. The one study that will settle whether injecting MOTS-c actually helps a person started enrolling in February 2026 and has not reported a result. That is the honest state of the evidence, not a gap to paper over.
- Zero completed, published human drug trials of native MOTS-c exist — the first one (Hudson Biotech, Phase 2a) began enrolling February 2026 and is still recruiting.
- The mouse/cell mechanistic evidence (AMPK activation, reversed diet-induced obesity/insulin resistance) is genuinely strong and consistent since 2015 — the gap is entirely on the human-trial side.
- The m.1382A>C genetic story is real and genuinely contested: linked to both a longevity hypothesis and, in a much larger study, to higher diabetes risk in men. Both are published; this page shows both.
- MOTS-c's own discoverer co-founded a company with a patent on MOTS-c analogs — a real, disclosed conflict of interest, stated precisely rather than inflated. That company has since dissolved.
- Explicitly banned in sport (WADA S4.4.1, no TUE available) — unlike SS-31 on this site, there is no regulatory ambiguity here.
- Not medical advice. Talk to your physician before using any experimental peptide, especially if you take diabetes medication, have active cancer, or are pregnant or breastfeeding — areas where this page genuinely cannot tell you it's low-risk, because nobody has studied it well enough yet to know.